TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications, including incretin therapies, to older adults. It recommends assessing function, nutrition and cognition before treatment and considering muscle loss, frailty, dehydration and team-based support.
The American Geriatrics Society (AGS) has published a clinical framework for prescribing obesity medications to older adults, urging clinicians to assess patients’ function, nutritional status and cognition before treatment. The case-based guidance addresses incretin therapies, including GLP-1 medications, and focuses on balancing potential benefits against age-related concerns such as frailty, muscle loss and dehydration.
The paper, developed by the AGS Healthy Aging Special Interest Group and published in the Journal of the American Geriatrics Society, applies the Geriatrics 5Ms framework to obesity medication use. The five areas are Mind, Mobility, Medications, Multicomplexity and Matters Most, a structure intended to help clinicians consider a patient’s health and priorities beyond body weight alone.
The authors say pretreatment assessment should cover functional status, nutritional adequacy and cognitive impairment. They also highlight potential risks for older adults, including loss of lean muscle, malnutrition and dehydration. The source report says older adults are underrepresented in clinical trials of these medications, leaving less evidence specific to this population.
The framework recommends pairing medication treatment with measures such as resistance training and adequate dietary protein. For some patients, the authors say coordinated care may involve a registered dietitian, physical therapist, fitness trainer or behavioral health professional. The report presents these as considerations for individualized care, not as a single treatment plan for every older adult.
Balancing Weight Goals With Function
For older adults, weight management decisions can intersect with mobility, strength, nutrition and independence. A treatment approach that focuses only on weight or blood sugar may miss changes in muscle mass, hydration or ability to carry out daily activities. The framework puts these factors into the prescribing discussion before medication begins.
That matters as clinicians weigh the reported potential benefits of obesity medicines, including support for weight management and glycemic control, against risks that may have particular relevance in later life. The paper does not establish that the drugs are unsafe for older adults; instead, it offers a way to assess individual circumstances and plan monitoring and supportive care. Its emphasis on patient priorities also leaves room for decisions shaped by what matters most to each person.
Products Worth Considering
Bowflex SelectTech 840 Adjustable Kettlebell
BowFlex Results Series SelectTech Dumbbells
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, 3 Modes, 2 Brush Heads and Travel Case
As an affiliate, we earn on qualifying purchases.
Applying the Geriatrics 5Ms
The framework is organized around clinical cases and adapts the Geriatrics 5Ms to incretin therapy. The model considers cognition and mental health under Mind, physical ability under Mobility, medication interactions under Medications, complex health needs under Multicomplexity and a patient’s own goals under Matters Most. The supplied report does not detail the individual cases, but describes the paper as a practical approach to prescribing.
Incretin therapies include GLP-1 medications that act through gut-derived hormonal pathways. The report says these medicines may offer benefits for weight management, glycemic control and other health conditions, while noting that older adults have been underrepresented in clinical trials. The new article, by Elias M. Wisdom and co-authors, was published in October 2026 with DOI 10.1111/jgs.70769.
“Safe prescribing requires pretreatment assessment of functional status, nutritional adequacy and cognitive impairment.”
— The framework authors, as summarized by Medical Xpress
Evidence Gaps and Individual Risks
The report does not provide trial results, prescribing thresholds or detailed instructions for choosing a specific medicine or dose. It also does not quantify how often older adults experience muscle loss, malnutrition or dehydration while taking these medications. Those questions cannot be resolved from the summary of the framework alone.
Because older adults are underrepresented in clinical trials, the size and limits of the evidence for this group remain a concern identified by the authors. The framework is guidance for clinicians, not proof that a particular approach improves outcomes. Individual risks, benefits and monitoring plans will depend on a patient’s health, medications and goals.
How Clinicians May Apply the Guidance
The publication gives clinicians a framework to use when considering obesity medications for older patients, with assessment before treatment and supportive measures built into care planning. The source report does not announce a rollout schedule, formal implementation program or additional study timeline.
Further research involving older adults could help clarify how these medicines affect function, lean muscle, nutrition and other outcomes over time. For now, the framework calls for individualized assessment and coordination among clinicians and relevant support professionals where appropriate. Patients should discuss medication decisions with their health care team rather than treating the article as personal prescribing advice.
Key Questions
What did the American Geriatrics Society publish?
The AGS published a case-based framework for clinicians prescribing obesity medications, including incretin therapies, to older adults. It applies the Geriatrics 5Ms to help guide patient-centered decisions.
What should clinicians assess before treatment?
The paper highlights functional status, nutritional adequacy and cognitive impairment. It also asks clinicians to consider frailty, muscle loss, malnutrition and dehydration risks.
Does the framework recommend medication for every older adult with obesity?
No. The report describes guidance for individualized prescribing, not a recommendation that every older adult use obesity medication. Decisions should account for a person’s health and priorities.
What support does the framework recommend alongside medication?
It recommends considering resistance training and adequate dietary protein. Some patients may benefit from coordinated support involving professionals such as dietitians or physical therapists.
What remains unknown about obesity medications in older adults?
The report says older adults are underrepresented in clinical trials. It does not provide specific outcome data, risk rates or a detailed dosing protocol for this population.
Source: medicalxpress.com
